Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context

References

• Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–171. doi:10.1016/j.critrevonc.2012.12.009
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Howlader NNA, Krapcho M, Miller D, et al. SEER cancer statistics review, 1975–2017; 2020.
   Google Scholar
• Kuhln A, Kirkwood A, Roddie C, et al. CAR T in patients with large B-cell lymphoma not fit for autologous transplant [epub ahead of print]. Br J Haematol. 2023. doi:10.1111/bjh.18810
   Google Scholar
• Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. doi:10.1186/2162-3619-1-36
   PubMedGoogle Scholar
• Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC. CD19 function in central and peripheral B-cell development. Immunol Res. 2005;31(2):119–131. doi:10.1385/ir:31:2:119
   PubMed Web of Science ®Google Scholar
• Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997;6(2):107–118. doi:10.1016/s1074-7613(00)80418-5
   PubMed Web of Science ®Google Scholar
• Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3(1):39–50. doi:10.1016/1074-7613(95)90157-4
   PubMed Web of Science ®Google Scholar
• Hojer C, Frankenberger S, Strobl LJ, et al. B-cell expansion and lymphomagenesis induced by chronic CD40 signaling is strictly dependent on CD19. Cancer Res. 2014;74(16):4318–4328. doi:10.1158/0008-5472.Can-13-3274
   PubMed Web of Science ®Google Scholar
• Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest. 2012;122(6):2257–2266. doi:10.1172/jci45851
   PubMed Web of Science ®Google Scholar
• Düll J, Topp M, Salles G. The use of tafasitamab in diffuse large B-cell lymphoma. Ther Adv Hematol. 2021;12:20406207211027458. doi:10.1177/20406207211027458
   Web of Science ®Google Scholar
• Makita S, Tobinai K. Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2018;29(5):1086–1089. doi:10.1093/annonc/mdy092
   PubMed Web of Science ®Google Scholar
• Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma. 2014;55(5):999–1006. doi:10.3109/10428194.2013.828354
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005–4010. doi:10.1073/pnas.0508123103
   PubMed Web of Science ®Google Scholar
• Salles G, Długosz-Danecka M, Ghesquières H, Jurczak W. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021;21(4):455–463. doi:10.1080/14712598.2021.1884677
   PubMed Web of Science ®Google Scholar
• Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049–8057. doi:10.1158/0008-5472.Can-08-2268
   PubMed Web of Science ®Google Scholar
• Woyach JA, Awan F, Flinn IW, et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014;124(24):3553–3560. doi:10.1182/blood-2014-08-593269
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Hess G, et al. A Phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: long-term follow-up, final analysis. Blood. 2019;134:4078. doi:10.1182/blood-2019-124297
   Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2018;29(5):1266–1272. doi:10.1093/annonc/mdy056
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Batoo SA. The emerging role of lenalidomide in the management of lymphoid malignancies. Ther Adv Hematol. 2011;2(1):45–53. doi:10.1177/2040620710390547
   PubMedGoogle Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811. doi:10.1200/jco.2014.59.5363
   PubMed Web of Science ®Google Scholar
• Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26(8):1667–1677. doi:10.1093/annonc/mdv102
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058–5066. doi:10.1002/cncr.26135
   PubMed Web of Science ®Google Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902–1909. doi:10.1038/leu.2013.95
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi:10.1016/S1470-2045(20)30225-4
   PubMed Web of Science ®Google Scholar
• Danielou-Lazareth A, Henry G, Geromin D, et al. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Eur J Immunol. 2013;43(5):1383–1388. doi:10.1002/eji.201242733
   PubMed Web of Science ®Google Scholar
• Sarkar S, Sabhachandani P, Ravi D, et al. Dynamic analysis of human natural killer cell response at single-cell resolution in B-cell non-Hodgkin lymphoma. Front Immunol. 2017;8:1736. doi:10.3389/fimmu.2017.01736
   PubMed Web of Science ®Google Scholar
• Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417–2426. doi:10.3324/haematol.2020.275958
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Duell J, González-Barca E, et al. Long-term subgroup analyses from L-mind, a Phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):19–21. doi:10.1182/blood-2020-140314
   Google Scholar
• Zinzani PL, Rodgers T, Marino D, et al. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2021;27(22):6124–6134. doi:10.1158/1078-0432.Ccr-21-1471
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Yoon DH, Peters A, et al. Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study. Clin Cancer Res. 2022;28(18):4003–4017. doi:10.1158/1078-0432.Ccr-21-3648
   PubMed Web of Science ®Google Scholar
• A trial to evaluate the efficacy and safety of tafasitamab with Bendamustine (BEN) Versus Rituximab (RTX) With BEN in adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) - full text view - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02763319. Accessed July 6, 2023.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. doi:10.1016/s1470-2045(18)30864-7
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640–654. doi:10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi:10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. doi:10.1016/S0140-6736(22)00662-6
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380(1):45–56. doi:10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2021;386(7):629–639. doi:10.1056/NEJMoa2116596
   PubMed Web of Science ®Google Scholar
• Ahmed N, Shahzad M, Shippey E, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther. 2022;28(7):358–364. doi:10.1016/j.jtct.2022.04.008
   PubMedGoogle Scholar
• Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi:10.1016/s1470-2045(21)00139-x
   PubMed Web of Science ®Google Scholar
• Hamadani M, Linhares Y, Gandhi M, et al. Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5). J Clin Oncol. 2022;40(16_suppl):TPS7591–TPS7591. doi:10.1200/JCO.2022.40.16_suppl.TPS7591
   Web of Science ®Google Scholar
• Shalabi H, Kraft IL, Wang HW, et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica. 2018;103(5):e215–e218. doi:10.3324/haematol.2017.183459
   PubMed Web of Science ®Google Scholar
• Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850–3852. doi:10.1182/bloodadvances.2020002587
   PubMed Web of Science ®Google Scholar
• Horvei P, Sakemura R, Cox MJ, et al. Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro. Biol Blood Marrow Transplant. 2020;26(3):S223–S224. doi:10.1016/j.bbmt.2019.12.201
   Web of Science ®Google Scholar
• Duell J, Obr A, Augustin M, et al. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leuk Lymphoma. 2022;63(2):468–472. doi:10.1080/10428194.2021.1986219
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165. doi:10.1200/jco.19.00172
   PubMed Web of Science ®Google Scholar
• Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022;6(2):533–543. doi:10.1182/bloodadvances.2021005794
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511–e522. doi:10.1016/S2352-3026(20)30120-4
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891). doi:10.1126/science.1158545
   PubMed Web of Science ®Google Scholar
• Dufner V, Sayehli CM, Chatterjee M, et al. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3(16):2491–2498. doi:10.1182/bloodadvances.2019000025
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a Phase I study. J Clin Oncol. 2016;34(10). doi:10.1200/JCO.2014.59.1586
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–1416. doi:10.1182/blood-2015-06-651380
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after Chimeric Antigen Receptor T-Cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6. doi:10.1182/blood-2019-123742
   PubMed Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a Phase I trial. J Clin Oncol. 2021;39(18):1959–1970. doi:10.1200/jco.20.03175
   PubMed Web of Science ®Google Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220–2231. doi:10.1056/NEJMoa2206913
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–1169. doi:10.1016/s0140-6736(21)00889-8
   PubMed Web of Science ®Google Scholar
• Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–e339. doi:10.1016/S2352-3026(22)00072-2
   PubMed Web of Science ®Google Scholar
• Patel K. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis. ASH; 2022.
   Google Scholar
• Budde E, Gopal AK, Kim WS, et al. A phase 1 dose escalation study of Igm-2323, a novel anti-CD20 x anti-CD3 IgM T Cell Engager (TCE) in patients with advanced B-cell malignancies. Blood. 2021;138:132. doi:10.1182/blood-2021-153355
   Google Scholar